secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001104659-24-113659
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged
--------------------------------------------------------------------------------

- FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.
- Q3 2024 prelim net product revenue $14.6M (vs $15.3M YoY); net loss $2.4M (vs $16.8M net income Q3 2023 which had $19.3M license payment).
- Nine-month 2024 net product revenue $42.5M (vs $44.4M); net loss $16.2M (vs $1.7M); R&D $9.6M includes $4.1M FDA fee and $3.0M milestone to DRL.
- FY 2024 guidance unchanged: net revenue $55-60M, SG&A $39-42M, R&D $9-10M.
- Approval triggered $15M milestone to Dr. Reddy's; mandatory $5M draw under SWK Credit; expects $4.4M recovery from 2021 cyber incident in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/0001104659-24-113659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/tm2427383d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-113659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer